Core Insights - The presentation of NEFECON at the IIgANN 2025 conference highlights its effectiveness and safety in treating IgA nephropathy, particularly after a 9-month treatment followed by a 12-month continuation, providing valuable evidence for long-term management of the disease [1][3] Group 1: Treatment Efficacy and Safety - NEFECON demonstrated significant efficacy in reducing 24-hour urinary protein levels from 1016 mg to 114 mg after 12 months, compared to 291 mg in the control group [3] - The treatment group showed a better change rate in eGFR compared to the control group, with no severe infections reported and only minor side effects observed, indicating good tolerability [3] Group 2: Clinical Need and Market Potential - There are over 5 million IgA nephropathy patients in China, with an annual increase of 100,000 new cases, indicating a pressing clinical need for effective treatments [1][5] - NEFECON's early market entry has allowed it to accumulate substantial real-world evidence, enhancing its competitive edge in terms of efficacy, safety, and accessibility [5] Group 3: Long-term Treatment Strategy - The latest research supports the strategy of "long-term targeted treatment" for IgA nephropathy, emphasizing the importance of maintaining kidney function while controlling proteinuria [3][4] - NEFECON is the first drug approved for IgA nephropathy treatment globally, with full approvals from multiple regulatory bodies, further solidifying its position in the market [3][5] Group 4: Commercial Performance - Following its inclusion in the national medical insurance directory, NEFECON's accessibility has significantly improved, with a monthly shipment volume exceeding 130,000 bottles and sales revenue reaching 520 million yuan in August 2025 [5] - Forecasts suggest that NEFECON's annual sales could exceed 1.2 to 1.4 billion yuan in 2025 and rise to 2.4 to 2.6 billion yuan in 2026, positioning it as a key drug in the field [5]
云顶新耀耐赋康®亮相IIgANN 2025：9个月疗程后延续用药12个月，IgA肾病患者持续获益获真实世界数据印证